secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2026-04-15T23:59:59+00:00
Accession:  0001171843-26-002458
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus receives FDA Fast Track designation for imdusiran in chronic hepatitis B
--------------------------------------------------------------------------------

- FDA granted Fast Track designation for imdusiran, an investigational therapy for chronic hepatitis B.
- Imdusiran has achieved functional cure in 10 chronic HBV patients in clinical trials to date.
- Fast Track may enable Accelerated Approval, Priority Review, or Rolling Review of a BLA or NDA.
- CEO Lindsay Androski said designation validates imdusiran as an important drug candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326002458/0001171843-26-002458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326002458/f8k_041426.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-002458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer